|
๐
|
Clinical and molecular delineation of the 17q21.31 microdeletion syndrome
50 auth.
D. Koolen,
Andrew J. Sharp,
Andrew J. Sharp,
Jane A. Hurst,
H. Firth,
S. Knight,
A. Goldenberg,
P. Saugier-Veber,
R. Pfundt,
L. Vissers,
A. Destrฤe,
B. Grisart,
Liesbeth Rooms,
N. Aa,
Michael Field,
...
A. Hackett,
Kathleen Bell,
Maลgorzata J. M. Nowaczyk,
G. M. Mancini,
P. Poddighe,
C. Schwartz,
Emilio Rossi,
M. Gregori,
L. Antonacci-Fulton,
M. McLellan,
J. Garrett,
M. Wiechert,
T. Miner,
Seth D. Crosby,
R. Ciccone,
L. Willatt,
Anita Rauch,
Martin Zenker,
S. Aradhya,
Melanie A. Manning,
T. Strom,
J. Wagenstaller,
A. Krepischi-Santos,
A. Vianna-Morgante,
Carla Rosenberg,
S. Price,
H. Stewart,
C. Shaw-Smith,
H. Brunner,
A O Wilkie,
J. Veltman,
O. Zuffardi,
Evan E. Eichler,
Evan E. Eichler,
B. Vries
|
7 |
2008 |
7
๐
|
|
๐
|
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
19 auth.
R. Dummer,
J. C. Brase,
J. Garrett,
C. D. Campbell,
E. Gasal,
M. Squires,
D. Gusenleitner,
M. Santinami,
V. Atkinson,
M. Mandalร ,
...
V. Chiarion-Sileni,
K. Flaherty,
J. Larkin,
C. Robert,
R. Kefford,
J. Kirkwood,
A. Hauschild,
D. Schadendorf,
G. Long
|
6 |
2020 |
6
๐
|
|
๐
|
Implementing liquid biopsies into clinical decision making for cancer immunotherapy
22 auth.
D. Quandt,
H. Zucht,
A. Amann,
A. Wulf-Goldenberg,
C. Borrebaeck,
M. Cannarile,
D. Lambrechts,
H. Oberacher,
J. Garrett,
T. Nayak,
...
Michael Kazinski,
C. Massie,
H. Schwarzenbach,
M. Maio,
R. Prins,
B. Wendik,
R. Hockett,
D. Enderle,
M. Noerholm,
H. Hendriks,
H. Zwierzina,
B. Seliger
|
6 |
2017 |
6
๐
|
|
๐
|
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
17 auth.
Mahrukh M. Syeda,
J. M. Wiggins,
Broderick C. Corless,
G. Long,
K. Flaherty,
D. Schadendorf,
P. Nathan,
C. Robert,
A. Ribas,
M. Davies,
...
J. Grob,
E. Gasal,
M. Squires,
M. Marker,
J. Garrett,
J. C. Brase,
D. Polsky
|
6 |
2021 |
6
๐
|
|
๐
|
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
15 auth.
H. Tawbi,
C. Robert,
J. C. Brase,
D. Gusenleitner,
E. Gasal,
J. Garrett,
A. Savchenko,
G. Gรถrgรผn,
K. Flaherty,
A. Ribas,
...
R. Dummer,
D. Schadendorf,
G. Long,
P. Nathan,
P. Ascierto
|
4 |
2022 |
4
๐
|
|
๐
|
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma.
16 auth.
Georgina V. Long,
A. Hauschild,
M. Santinami,
V. Atkinson,
M. Mandalร ,
V. Chiarion-Sileni,
J. Larkin,
C. Robert,
D. Schadendorf,
Kohinoor Dasgupta,
...
M. Shilkrut,
J. Garrett,
J. C. Brase,
R. Kefford,
J. M. Kirkwood,
Reinhard Dummer
|
3 |
2018 |
3
๐
|
|
๐
|
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
25 auth.
J. C. Brase,
R. Walter,
A. Savchenko,
D. Gusenleitner,
J. Garrett,
T. Schimming,
R. Vรกraljai,
D. Castelletti,
J. Kim,
N. Dakappagari,
K. Schultz,
C. Robert,
G. Long,
P. Nathan,
A. Ribas,
...
K. Flaherty,
B. Karaszewska,
J. Schachter,
A. Sucker,
K. Schmid,
L. Zimmer,
E. Livingstone,
E. Gasal,
D. Schadendorf,
A. Roesch
|
3 |
2021 |
3
๐
|
|
๐
|
Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis
10 auth.
G. Sociรฉ,
D. Niederwieser,
N. von Bubnoff,
M. Mohty,
J. Szer,
R. Or,
...
J. Garrett,
A. Prahallad,
C. Wilke,
R. Zeiser
|
1 |
2023 |
1
๐
|
